PTC Therapeutics CLO Executes $408,612 in Stock Sales, Exercises Options Under 10b5-1 Plan
PTC Therapeutics executive vice president and chief legal officer Mark Elliott Boulding sold 5,894 shares of company stock on February 17 and 18, 2026, generating $408,612 in proceeds. The transactions were conducted under a Rule 10b5-1 trading arrangement. Separately, Boulding exercised options to acquire 2,813 shares at $25.69 per share. The insi…